Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic

作者: Thomas Stricker , Daniel V.T. Catenacci , Tanguy Y. Seiwert

DOI: 10.1053/J.SEMINONCOL.2011.01.013

关键词:

摘要: Cancers arise as a result of an accumulation genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set molecular changes. Technologies have been developed to study cancers and derive characteristics increasingly implications for clinical care. Indeed, the identification key (molecular drivers) may ultimately translate into dramatic benefit patients through development highly targeted therapies. With increasing availability newer, more powerful, cheaper technologies such multiplex mutational screening, next generation sequencing, array-based approaches can determine gene copy numbers, methylation, expression, others, well sophisticated interpretation high-throughput information using bioinformatics tools like signatures predictive algorithms, will routinely be characterized in near future. This review examines background clinicians physician-scientists need interpret order develop better, personalized treatment strategies.

参考文章(74)
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat, Roel GW Verhaak, Katherine A Hoadley, D Neil Hayes, Charles M Perou, Heather K Schmidt, Li Ding, Richard K Wilson, David Van Den Berg, Hui Shen, Henrik Bengtsson, Pierre Neuvial, Leslie M Cope, Jonathan Buckley, James G Herman, Stephen B Baylin, Peter W Laird, Kenneth Aldape, None, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. ,vol. 17, pp. 510- 522 ,(2010) , 10.1016/J.CCR.2010.03.017
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Peter J. O'Dwyer, Richard J. Lee, Joseph F. Grippo, Keith Nolop, Paul B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine. ,vol. 363, pp. 809- 819 ,(2010) , 10.1056/NEJMOA1002011
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang, Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1626- 1634 ,(2008) , 10.1200/JCO.2007.14.7116
Sumithra J. Mandrekar, Daniel J. Sargent, Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges Journal of Clinical Oncology. ,vol. 27, pp. 4027- 4034 ,(2009) , 10.1200/JCO.2009.22.3701
Hongwu Zheng, Haoqiang Ying, Haiyan Yan, Alec C. Kimmelman, David J. Hiller, An-Jou Chen, Samuel R. Perry, Giovanni Tonon, Gerald C. Chu, Zhihu Ding, Jayne M. Stommel, Katherine L. Dunn, Ruprecht Wiedemeyer, Mingjian J. You, Cameron Brennan, Y. Alan Wang, Keith L. Ligon, Wing H. Wong, Lynda Chin, Ronald A. DePinho, p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation Nature. ,vol. 455, pp. 1129- 1133 ,(2008) , 10.1038/NATURE07443
Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron, Charles E. Geyer, John Forster, Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer The New England Journal of Medicine. ,vol. 355, pp. 2733- 2743 ,(2006) , 10.1056/NEJMOA064320
Rihab Nasr, Marie-Claude Guillemin, Omar Ferhi, Hassan Soilihi, Laurent Peres, Caroline Berthier, Philippe Rousselot, Macarena Robledo-Sarmiento, Valérie Lallemand-Breitenbach, Bernard Gourmel, Dominique Vitoux, Pier Paolo Pandolfi, Cécile Rochette-Egly, Jun Zhu, Hugues de Thé, Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine. ,vol. 14, pp. 1333- 1342 ,(2008) , 10.1038/NM.1891
Michael L. Metzker, Sequencing technologies — the next generation Nature Reviews Genetics. ,vol. 11, pp. 31- 46 ,(2010) , 10.1038/NRG2626
M. L. Gatza, J. E. Lucas, W. T. Barry, J. W. Kim, Q. Wang, M. D. Crawford, M. B. Datto, M. Kelley, B. Mathey-Prevot, A. Potti, J. R. Nevins, A pathway-based classification of human breast cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 6994- 6999 ,(2010) , 10.1073/PNAS.0912708107
Fréderic Bibeau, Marie-Danièle Diebold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean-François Emile, Frédérique Penault-Llorca, Pierre Laurent-Puig, Astrid Lièvre, Jean-Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Journal of Clinical Oncology. ,vol. 26, pp. 374- 379 ,(2008) , 10.1200/JCO.2007.12.5906